Mikhail Blagosklonny is a respected scientist. His studies focus on cancer and aging. Presently, he is a professor of oncology at the New York based Roswell Cancer Institute. Throughout his life, Blagosklonny has been interested in science. He enrolled in First Pavlov Medical University where he graduated with his MD in internal medicine. He also holds a PhD in experimental medicine from the St. Petersburg based university. In 2002, Blagosklonny was hired by the New York Medical College to work as an associate professor of medicine. Later, he moved to Ordway Research Institute where he served as a senior scientist. Blagosklonny worked for the institute until 2009 when Roswell Park Cancer Institute recruited him. Follow Mikhail on Google Scholar
Over the years, he has shared his experiences and knowledge to the employees of Roswell Cancer Institute. Mainly, the corporation focuses on cancer research and treatment. Dr. Roswell Park established the institute in 1898. It is regarded as the first medical facility to devote its resources and time to cancer research and treatment in the United States. In upstate New York, Roswell Park is the only institution that holds the National Cancer Institute’s comprehensive cancer center designation. Blagosklonny and other specialists in the institution have been sharing different ideas and potential approaches to fighting cancer. One of these ideas is the tissue specific therapy of cancer.
His research interests center on targeted cancer therapies that shield normal cells from destruction. In addition, Blagosklonny’s research focuses on the essential mechanisms of anti-aging drugs and biogerontology. Mikhail has formulated a hypothesis on the probable role of TOR signaling in cancer and aging. The professor has been a leading supporter of the use of rapamycin, a prominent drug used for cancer treatment. It lengthens the life of cancer patient.
Blagosklonny is the editor in chief of Cell Cycle and Oncotarget, a weekly journal that focuses on oncology. It was founded in 2010. He is also the Cancer therapy and Biology’s editor. Mikhail Blagosklonny is the founding editor of the American Journal of Pathology, Cancer Research, Cell Death and Differentiation, and the International Journal of Cancer. He has written over 270 papers, which have been published on peer-reviewed journals. Blagosklonny has an h-index of 83. This is because he has more than 25,000 citations. Visit classroomvoices.org to read more about Mikhail.